Recent News

• 03.11.2025 - Leerink Partners Global Healthcare Conference
• 03.05.2025 - David-Alexandre Gros, MD, on Addressing Unmet Needs in End Stage Kidney Disease With Genetically Modified Porcine Kidney Transplant
• 03.04.2025 - Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference
• 02.27.2025 - Scrip Asks… What Does 2025 Hold For Biopharma? Part 6: Therapeutic Area Advances
• 02.27.2025 - CD40L Blocker Tegoprubart Playing Key Role in Xenotransplantation
• 02.12.2025 - A Second Person Has Received a Pig Kidney Transplant
• 02.12.2025 - For Second Kidney Xenotransplant Patient Discharged, Immunosuppression Is Key
• 02.12.2025 - eGenesis announces 2nd pig kidney procedure success, as xenotransplantation field moves forward
• 02.12.2025 - Second Xenotransplant with Gene-Edited Pig Kidney Performed at Mass General
• 02.07.2025 - Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Recent Filings

• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.13.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.13.2025 - 4 Statement of changes in beneficial ownership of securities